Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years
|
Oct 2019
|
Blood Advances
|
aplastic anemia
|
Guideline-based indicators for adult patients with myelodysplastic syndromes
|
Aug 2020
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
Risk and timing of cardiovascular death among patients with myelodysplastic syndromes
|
Oct 2017
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
|
Feb 2021
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1
|
Mar 2017
|
Blood Advances
|
acute myeloid leukemia (AML)
|
Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors
|
Feb 2021
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes
|
Oct 2019
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
|
Nov 2020
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
|
Mar 2015
|
Blood Cancer J
|
myelodysplastic syndromes (MDS)
|
Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes
|
Sep 2017
|
Blood Cancer J
|
myelodysplastic syndromes (MDS)
|